KALA BIO, Inc.
Close on Oct 19, 2026
- Market cap
- $14.28K
- P/E (TTM)
- –
- Dividend yield
- –
About Kala Bio
Pharmaceutical Preparations, SIC 2834
KALA BIO, Inc. is a transitioning biopharmaceutical company that focuses on developing an on-premises artificial intelligence infrastructure platform tailored for the biotechnology and pharmaceutical sectors. Operating through its licensed Researgency platform, the company intends to provide platform-as-a-service offerings, implementation support, data analytics, and maintenance subscriptions. These tools allow biotechnology firms, pharmaceutical enterprises, and contract research organizations to analyze biological datasets, coordinate research workflows, and preserve data sovereignty within private environments. Concurrently, the company seeks to monetize its proprietary mesenchymal stem cell secretome biologics portfolio through licensing, sales, or partnerships following the discontinuation of its clinical-stage candidate KPI-012.
Historically, the enterprise conducted preclinical evaluations and clinical trials across 45 sites in the United States, alongside additional operations initiated in Mexico and Argentina. The provided filing text does not report current employee headcount, facility figures, or active corporate headquarters locations.
Summary of the business section of Kala Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- KALA BIO, Inc.
- Founded
- 2009
- Headquarters
- Arlington, MA
- Address
- 1167 Massachusetts Avenue 02476
- Phone
- (781) 996-5252
- Website
- www.kalarx.com
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- HTL International, LLC, Houston, Texas
Stock & identifiers
- Ticker
- KALA
- Exchange
- Nasdaq
- IPO date
- Jul 20, 2017
- Shares outstanding
- 19M, Aug 14, 2026
- Public float
- $24.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, May 11, 2026; 1-for-50 reverse, May 8, 2026; 1-for-50 reverse, Oct 21, 2022; 1-for-50 reverse, Oct 20, 2022
- SEC CIK
- 1479419
- CUSIP
- 483119301
- ISIN
- US4831193010
- LEI
- 529900Y7RO0C9P0TX474
- EIN
- 27-0604595
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Avraham Minkowitz | Chief Executive Officer, Director | – |
| David E. Lazar | Chief Executive Officer, Director | 0 |
| Romulus K. Brazzell | SEE REMARKS | 35,952 |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | 28,906 |
| Darius Kharabi | CHIEF BUSINESS OFFICER | 41,760 |
| Brendan P. Purdy | Director | – |
| Yonatan C. Colman | Director | – |
| Chaim D. Berger | Director | – |
| Hillel D. Posen | Director | – |
| Todd Bazemore | Director | 35,933 |
| Mark T. Iwicki | Director | 103,540 |
| Andrew I. Koven | Director | 16,972 |
| Howard B. Rosen | Director | 16,502 |
| Gregory D. Perry | Director | 13,344 |
| C. Daniel Myers | Director | 10,374 |
| Marjan Farid | Director | 10,242 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $906.64K | -$1.01M | $2.42M | $1 | – |
| FY2024 | $1.49M | $1.26M | $935.12K | $7 | – |
| FY2023 | $8.34M | $3.75M | $2.93M | $2 | – |
| FY2022 | $1.87M | $1.22M | $1.01M | $11 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025 and March 31, 2026, we had a total of 6 full-time employees.”
Corporate history
Events identified from SEC filings